Novartis logo

Novartis(NYSE) NVS

Market Cap$258.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1991)+4,215%
5 Year+119%
1 Year+11%
1 Month-13%
Premium Feature
Moneyball Superscore
87/100
$140.89
-0.08%
-0.11Today
After hours$140.91+$0.02 (+0.01%)
Novartis last closing stock price
MetricPriceDate
Last closeUSD 141.002026-10-02
Novartis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.07%USD 145.462026-09-25
1 month-13.21%USD 162.462026-09-02
3 month-11.82%USD 159.902026-07-02
Year to date+5.36%USD 133.832025-12-31
1 year+10.91%USD 127.132025-10-02
3 year+66.07%USD 84.912023-10-03
5 year+118.95%USD 64.402021-10-01
Since inception+4,215.46%USD 3.271991-11-18

Novartis Financials at a Glance

Market Cap

$258.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$55.63B

Net Income (TTM)

$12.76B

EPS (TTM)

$6.63

P/E Ratio

21.15

Dividend

$4.74

Beta (Volatility)

0.33 (Low)

Price

$140.89

Volume

1,329,069.145

Open

$141.02

Previous Close

$140.93

Daily Range

$139.31 - $141.02

52-Week Range

$121.57 - $170.46

Estimated Earnings Date

Oct 27, 2026

NVS News

GettyImages-941740978-1201x801-d21b45d

The Largest Healthcare Companies by Market Cap in October 2026

Lyle DalyOct 4, 2026
office_building_commercial_real_estate

5 Best Commercial Real Estate Stocks for 2026

Kristi WaterworthSep 29, 2026
Person looking at computer and writing in book.

Best ESG ETFs to Buy in 2026

Robin Hartill, CFPAug 25, 2026
Pharmacist talking to patient

3 Dividend Stocks to Buy for a Lifetime of Passive Income

Prosper Junior BakinyJul 29, 2026
TMF-Pills-Blue-StockVStock.png

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Brendan CoffeyJul 9, 2026
Patient about to take medicine.

Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now

Prosper Junior BakinyMar 3, 2026
growing your money, coins, dividends, time

How to Invest in Vanguard International High Dividend Yield ETF (VYMI)

Tony DongFeb 27, 2026
Person sitting and working at a desk.

Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?

Prosper Junior BakinyFeb 24, 2026
Page 1

NVS: Motley Fool Moneyball Superscore

87

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novartis

Novartis AG is a global healthcare company focused on developing, manufacturing, and marketing innovative healthcare products. The company specializes in prescription medicines, particularly in oncology, immunology, neuroscience, and cardiovascular diseases, while also offering a range of established brands and specialized therapies.

Products and Services
  • Innovative prescription medicines in oncology and immunology
  • Specialized therapies for various chronic conditions
  • Established older brands in the healthcare sector
Growth Outlook
  • Revenue of $14.42 billion in Q2 2026, showing strong demand
  • Net income of $3.27 billion in Q2 2026, reflecting profitability
  • Consistent R&D investment of approximately $2.76 billion in Q2 2026
Financial Highlights
  • Trailing twelve months (TTM) revenue of $54.5 billion, indicating robust performance
  • Net profit margin of 23.09% TTM, showcasing operational efficiency
  • Dividend yield of 3.24% TTM, appealing for income-focused investors
Novartis AG stands out in the healthcare sector due to its commitment to innovation and strong financial performance. The company has consistently delivered impressive revenue figures, with a TTM revenue of $54.5 billion, underscoring its market presence. The net profit margin of 23.09% reflects effective cost management and operational efficiency, making it a competitive player in the pharmaceutical industry. Additionally, the company’s dividend yield of 3.24% offers an attractive return for investors seeking income. With a focus on research and development, Novartis continues to invest significantly in new therapies, ensuring future growth and sustainability in a rapidly evolving healthcare landscape.
AI Generated • Sep 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

75,267

CEO

Vasant Narasimhan, MD

Website

www.novartis.com

Headquarters

Basel, BS 4056, CH

NVS Financials

Key Financial Metrics (TTM)

Gross Margin

74.29%

Operating Margin

29.86%

Net Income Margin

23.09%

Return on Equity

29.64%

Return on Capital

20.53%

Return on Assets

10.34%

Earnings Yield

4.73%

Dividend Yield

3.36%

Payout Ratio

67.77%

Stock Overview

Market Cap

$258.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.83B

Volume

1.33M

Avg. Volume

1.96M

Financials (TTM)

Gross Profit

$41.41B

Operating Income

$16.99B

EBITDA

$22.26B

Operating Cash Flow

$18.39B

Capital Expenditure

-$2.57B

Free Cash Flow

$15.82B

Cash & ST Invst.

$7.69B

Total Debt

$49.01B

Novartis Performance Analysis

Novartis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 42,288,270,587-18.1%
20232023-12-31USD 45,602,599,2897.8%
20242024-12-31USD 50,288,540,49010.3%
20252025-12-31USD 54,811,252,2069.0%
Novartis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-29-3.2%
Q42025-12-31-7.1%
Q12026-03-311.4%
Q22026-06-306.6%
Novartis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 3.17-70.1%
20232023-12-31USD 7.12124.6%
20242024-12-31USD 5.86-17.7%
20252025-12-31USD 7.1922.6%
Novartis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-29-1.9%
Q42025-12-31-38.1%
Q12026-03-3132.0%
Q22026-06-303.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$14.42B

-2.8%

Gross Profit

$10.74B

-6.7%

Gross Margin

74.47%

N/A

Market Cap

$258.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.43M

N/A

Employees

75,267

N/A

Net Income

$3.27B

-19.2%

EBITDA

$5.94B

-2.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$7.69B

+9.9%

Total Debt

$49.01B

+50.2%

Accounts Receivable

$9.85B

+7.4%

Inventory

$6.22B

-1.4%

Long Term Debt

$39.15B

+62.7%

Short Term Debt

$9.86B

+15.0%

Return on Assets

10.34%

N/A

Return on Invested Capital

18.07%

N/A

Free Cash Flow

$5.57B

-8.8%

Operating Cash Flow

$5.89B

-11.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,777.74+0.01%
^DJIDJI
$51,304.21+0.00%
^IXICNASDAQ
$27,461.27+0.01%
BTCBitcoin
$85,510.00+0.00%

Questions About NVS

What is the current price of Novartis?

Novartis is trading at $140.93 per share.

What is the 52-week range for Novartis?

Over the past 52 weeks, Novartis has traded between $121.57 and $170.46.

How much debt does Novartis have?

As of the most recent reporting period, Novartis reported total debt of $49.01B.

How much cash does Novartis have on hand?

Novartis reported $7.62B in cash and cash equivalents in its most recent financial results.

What is Novartis’s dividend yield?

Novartis currently has a dividend yield of 3.36%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services